Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MabionCD20 vs MabThera in Rheumatoid Arthritis
NCT02468791Phase 3Completed
- Sponsor
- Mabion S.A.
- Start
- May 2013
- Primary completion
- May 2017
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 3 trial of MabionCD20 in rheumatoid arthritis (RA), sponsored by Mabion S.A.. Started May 2013; status: completed.
02
Drugs
MabionCD20
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02468791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02468791.